196 related articles for article (PubMed ID: 32237023)
1. Isoniazid-phytochemical conjugation: A new approach for potent and less toxic anti-TB drug development.
Swain SS; Paidesetty SK; Padhy RN; Hussain T
Chem Biol Drug Des; 2020 Aug; 96(2):714-730. PubMed ID: 32237023
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
3. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
Martins F; Ventura C; Santos S; Viveiros M
Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
[TBL] [Abstract][Full Text] [Related]
4.
Jagadeb M; Rath SN; Sonawane A
J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
[TBL] [Abstract][Full Text] [Related]
5. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
[TBL] [Abstract][Full Text] [Related]
6. Anti-Mycobacterium tuberculosis activity of naphthoimidazoles combined with isoniazid and rifampicin.
Corrêa Barros LP; Del Rio KP; Carvalho TDSC; Pinto MDCFR; de Moura KCG; Halicki PCB; Ramos DF; da Silva PEA
Tuberculosis (Edinb); 2018 Jul; 111():198-201. PubMed ID: 30029908
[TBL] [Abstract][Full Text] [Related]
7. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
[TBL] [Abstract][Full Text] [Related]
8. The Effects Study of Isoniazid Conjugated Multi-Wall Carbon Nanotubes Nanofluid on
Zomorodbakhsh S; Abbasian Y; Naghinejad M; Sheikhpour M
Int J Nanomedicine; 2020; 15():5901-5909. PubMed ID: 32884258
[TBL] [Abstract][Full Text] [Related]
9. Hybrid Design of Isonicotinic Acid Hydrazide Derivatives: Machine Learning Studies, Synthesis and Biological Evaluation of their Antituberculosis Activity.
Kovalishyn V; Hodyna D; Sinenko VO; Blagodatny V; Semenyuta I; Slivchuk SR; Brovarets V; Poda G; Metelytsia L
Curr Drug Discov Technol; 2020; 17(3):365-375. PubMed ID: 30973110
[TBL] [Abstract][Full Text] [Related]
10. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
12. New hydrazides derivatives of isoniazid against Mycobacterium tuberculosis: Higher potency and lower hepatocytotoxicity.
Castelo-Branco FS; de Lima EC; Domingos JLO; Pinto AC; Lourenço MCS; Gomes KM; Costa-Lima MM; Araujo-Lima CF; Aiub CAF; Felzenszwalb I; Costa TEMM; Penido C; Henriques MG; Boechat N
Eur J Med Chem; 2018 Feb; 146():529-540. PubMed ID: 29407978
[TBL] [Abstract][Full Text] [Related]
13. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
14. Enhancing antimycobacterial activity of isoniazid and rifampicin incorporated norbornene nanoparticles.
Kumarasingam K; Vincent M; Mane SR; Shunmugam R; Sivakumar S; Uma Devi KR
Int J Mycobacteriol; 2018; 7(1):84-88. PubMed ID: 29516891
[TBL] [Abstract][Full Text] [Related]
15. Antituberculosis drug resistance in isolates of Mycobacterium tuberculosis complex in southeast Spain.
Montiel Quezel-Guerraz N; Sánchez-Porto A; Ortega Torres M; Pérez Santos MJ; Acosta F; Guzman A; Correa Ruiz A; Bérmudez Ruiz P
J Glob Antimicrob Resist; 2020 Mar; 20():183-186. PubMed ID: 31421285
[TBL] [Abstract][Full Text] [Related]
16. Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic.
Isakova J; Sovkhozova N; Vinnikov D; Goncharova Z; Talaibekova E; Aldasheva N; Aldashev A
BMC Microbiol; 2018 Mar; 18(1):22. PubMed ID: 29566660
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Anyplex™ II MTB/MDR kit's performance to rapidly detect isoniazid and rifampicin resistant Mycobacterium tuberculosis from various clinical specimens.
Chumpa N; Kawkitinarong K; Rotcheewaphan S; Sawatpanich A; Petsong S; Tumwasorn S; Suwanpimolkul G
Mol Biol Rep; 2020 Apr; 47(4):2501-2508. PubMed ID: 32124172
[TBL] [Abstract][Full Text] [Related]
18. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.
Maningi NE; Malinga LA; Antiabong JF; Lekalakala RM; Mbelle NM
BMC Infect Dis; 2017 Dec; 17(1):795. PubMed ID: 29282012
[TBL] [Abstract][Full Text] [Related]
19. Recent updates on drug resistance in Mycobacterium tuberculosis.
Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
[TBL] [Abstract][Full Text] [Related]
20. Capacity of Abbott RealTi
Hofmann-Thiel S; Molodtsov N; Duffner C; Kadyrov A; Kalmambetova G; Kabirov O; Rajabov A; Parpieva N; Sayfutdinov Z; Vogel M; Vogel H; Antonenka U; Hoffmann H
Int J Tuberc Lung Dis; 2019 Apr; 23(4):458-464. PubMed ID: 31064625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
